ONCOASSAY™ LUNG HELPS LUNG CANCER SUFFERERS AND THEIR CLINICIANS TO DECIDE WHICH TREATMENT WILL BE MOST BENEFICIAL, BASED ON THE TUMOR TYPE AND ITS ACTIVITY
If you are diagnosed with lung cancer, your clinician may have explained to you that you may receive chemotherapy or another "targeted" therapy.
The problem is that, although each of these therapies can be very powerful in preventing the return of your cancer, it is extremely difficult to determine which to use and how useful each will be in treating your own specific cancer type.
ONCOASSAY™ LUNG is for people who have been diagnosed with non-small cell lung cancer and are advised to have follow up treatment, after removal of the cancer, to prevent its return or spread.
ONCOASSAY™ LUNG characterizes your tumor's own genetic profile; based on this it determines which treatment you are likely to respond to.
It enables you and your clinician to understand whether chemotherapy or another treatment will be of most benefit to you and so to make informed choices about your treatment.
If repeated during your course of treatment, it will immediately alert you to changes in your tumor that may indicate that it is time to switch to a different treatment.
ONCOASSAY™ LUNG uses HEALI's powerful algorithm and decision tools to measure the risk of your cancer returning and its likely response to treatment by combining the results of analysis of 6 biomarkers (biological markers) taken from your tumor.
The results, summarized as the OA Score (ONCOASSAY Score) forms the basis for you and your clinician to develop a personalized therapy strategy based on the activity of your own tumor type.
If repeated during your course of treatment, it will also tell you whether your cancer has developed resistance to the therapy and advise on an alternative treatment that is now more suitable.
ST JOHN'S INNOVATION CENTRE
HEALI Limited is a company registered in England no. 08693232